Alto Neuroscience, Inc. logo

Alto Neuroscience, Inc.(ANRO)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
WEAK BUY
BUY for 6 days
PROFIT SINCE LAST BUY
-14.12% ▼
LAST CLOSE
$25.37
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ANRO

11/20/2026: ANRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that develops precision medicines for neuropsychiatric disorders using a proprietary biomarker platform. The company's primary strength lies in its biomarker-driven approach and a diversified clinical pipeline featuring multiple mid-to-late-stage candidates like ALTO-100, ALTO-300, and ALTO-207. Its primary investment growth story centers on redefining psychiatry and achieving key clinical data readouts that could validate its platform. Key risks include clinical trial uncertainty, lack of commercial revenue, and operational losses typical of pre-commercial biotech firms. The stock best suits growth-oriented investors with a high risk tolerance who are willing to monitor upcoming clinical catalysts and financial runway.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fit while signal remains positiveAlto offers high potential clinical-stage growth tied to innovative biomarker-driven psychiatry pipelines.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp upside movements around major clinical data readouts and financing announcements.
Value investorWeak fitAs a pre-commercial biotechnology company with ongoing net losses, it lacks traditional value or earnings metrics.
Dividend investorWeak fitThe company does not pay dividends, retaining all capital for drug development.
Low-risk investorWeak fitHigh clinical development and regulatory volatility make it unsuitable for risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience dramatic price swings based on trial results and news flow.
Valuation riskHighValuations are driven by clinical potential rather than current earnings or revenue generation.
Competition risk (CNS drug development)Medium / highThe neuropsychiatry space features many competitors developing alternative therapies for depression and schizophrenia.
Business qualityMediumAlto possesses a scientifically rigorous platform, but long-term commercial viability remains unproven.
Dividend incomeLow / noneNo dividend is paid or expected in the foreseeable future.
Execution riskHighSuccess depends heavily on successful clinical trial execution, patient enrollment, and regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.02B USD
Price to earnings Ratio -
1Y Target Price 38.67
Price to earnings Ratio -
1Y Target Price 38.67
Volume (30-day avg) 669.8K shares
Beta 1.45
52 Weeks Range 12.51 - 37.48
Updated Date 11/21/2026
52 Weeks Range 12.51 - 37.48
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.32

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -9.13%
Avg. Invested days 31
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ANRO receives a 3-star rating, supported by strong analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
ANRO has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: slightly negative earnings growth (-2.9%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
ANRO's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ANRO's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-2.9%, slightly negative) and free-cash-flow growth (-4.6%, slightly negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 103.3% and approximately 75.9% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 4.12% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Alpha Wave Global LP 9.28%
COMMODORE CAPITAL LP 6.81%
BlackRock Inc 5.31%
Spruce Street Capital LP 4.19%
Perceptive Advisors LLC 4.03%

Unit Economics (Per $1K Revenue)

★★★★★
ANRO generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
ANRO has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Product Sales & LicensingFuture commercialization of precision psychiatry drug candidates such as ALTO-100, ALTO-300, and ALTO-207, or potential milestone and royalty payments from partnership agreements.The company currently makes no commercial money and operates entirely on external financing and cash reserves while developing its drug pipeline.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 762.01M
Price to Sales(TTM) -
Enterprise Value 762.01M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 40.11M
Shares Floating 30.46M
Shares Outstanding 40.11M
Shares Floating 30.46M
Percent Insiders 4.12
Percent Institutions 103.28

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.